ORIC Pharmaceuticals, Inc.
- Open
- 13.05
- Day high
- 13.06
- Day low
- 12.82
- Prev close
- 12.99
- Volume
- 17K
- Mkt cap
- $1.3B
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 3.5
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$1.2M over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions accumulating (13F)
ORIC Pharmaceuticals, Inc. (ORIC) is a Healthcare company listed on NASDAQ. The stock is up 22% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4).
ORIC Pharmaceuticals, Inc. (ORIC) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ORIC earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 3, 2026 | $-0.36 | $-0.38 | -5.7% | — | — |
| May 4, 2026 | $-0.31 | $-0.34 | -9.7% | — | — |
| Nov 13, 2025 | $-0.41 | $-0.33 | +19.5% | — | — |
| Feb 18, 2025 | $-0.52 | $-0.51 | +1.9% | $533000 | — |
| Mar 11, 2024 | $-0.49 | $-0.49 | +0.0% | $2M | — |
| Aug 10, 2023 | $-0.58 | $-0.50 | +13.8% | — | — |
| Mar 16, 2023 | $-0.56 | $-0.52 | +7.1% | — | — |
| Aug 11, 2022 | $-0.60 | $-0.51 | +15.0% | — | — |
| Mar 21, 2022 | $-0.61 | $-0.58 | +4.9% | — | — |
| Aug 10, 2021 | $-0.50 | $-0.57 | -14.0% | — | — |
| May 6, 2021 | $-0.48 | $-0.45 | +6.2% | — | — |
| Mar 23, 2021 | $-0.50 | $-0.84 | -68.0% | — | — |
ORIC insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 28, 2026 | Piscitelli Dominicofficer: Chief Financial Officer | Sell | 77,000 | $13.69 |
| Aug 28, 2026 | Piscitelli Dominicofficer: Chief Financial Officer | Option | 52,000 | $4.36 |
| Aug 28, 2026 | Piscitelli Dominicofficer: Chief Financial Officer | Option | 25,000 | $6.00 |
| Jul 28, 2026 | Heyman Richard A.director | Option | 3,500 | $1.60 |
| Jul 28, 2026 | Heyman Richard A.director | Sell | 6,100 | $12.02 |
| Jul 28, 2026 | Heyman Richard A.director | Sell | 7,000 | $12.02 |
| Jul 8, 2026 | Heyman Richard A.director | Sell | 300 | $12.00 |
| Feb 26, 2026 | Piscitelli Dominicofficer: Chief Financial Officer | Sell | 52,000 | $13.51 |
| Feb 26, 2026 | Piscitelli Dominicofficer: Chief Financial Officer | Option | 52,000 | $4.36 |
| Jan 20, 2026 | Heyman Richard A.director | Sell | 3,500 | $12.00 |
| Jan 20, 2026 | Heyman Richard A.director | Sell | 3,200 | $12.00 |
| Jan 6, 2026 | Hoerter Steven L.director | Grant | 40,000 | $8.17 |
| Jan 6, 2026 | Chacko Jacobdirector, officer: PRESIDENT AND CEO | Grant | 675,000 | $8.17 |
| Jan 6, 2026 | Chacko Jacobdirector, officer: PRESIDENT AND CEO | Grant | 112,500 | — |
| Jan 6, 2026 | Piscitelli Dominicofficer: Chief Financial Officer | Grant | 206,500 | $8.17 |
Source: ORIC SEC Form 4 filings, latest Aug 28, 2026. For informational purposes only — not investment advice.
See the full ORIC insider & 13F page →ORIC Pharmaceuticals, Inc. company profile
Overview
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California. The company went public in April 2020 and focuses on discovering and developing precision cancer therapies that target specific resistance mechanisms in oncology. ORIC operates as a research-driven organization that aims to overcome the challenges patients face when their cancers become resistant to existing treatments, including both chemotherapy and newer immunotherapy approaches.
Business
ORIC Pharmaceuticals operates in the precision oncology sector of biotechnology, specifically targeting cancer drug resistance mechanisms. The company develops small molecule inhibitors and other targeted therapies designed to overcome the ways cancer cells evade or become resistant to treatment. The company's pipeline consists of three main clinical-stage programs. ORIC-533 is an orally bioavailable small molecule inhibitor of CD73, an enzyme that cancer cells use to suppress immune responses and resist both chemotherapy and immunotherapy treatments. CD73 converts adenosine monophosphate to adenosine, which creates an immunosuppressive tumor environment that helps cancer cells hide from the immune system. ORIC-944 represents a different approach, functioning as an allosteric inhibitor of polycomb repressive complex 2 (PRC2), specifically targeting prostate cancer. PRC2 is a protein complex that regulates gene expression through epigenetic modifications, and its dysregulation is associated with cancer progression and treatment resistance. The third clinical program, ORIC-114, is a brain-penetrant oral inhibitor designed to selectively target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). This compound specifically targets exon 20 insertion mutations, which are genetic alterations that make cancers particularly difficult to treat with existing EGFR inhibitors. Beyond these clinical programs, ORIC maintains multiple discovery-stage precision medicines targeting various other cancer resistance mechanisms. The company operates through licensing agreements, including partnerships with Voronoi Inc. and Mirati Therapeutics, Inc., which provide access to additional technologies and compounds for development.
Revenue model
ORIC Pharmaceuticals operates under a typical clinical-stage biopharmaceutical business model, where the company currently generates minimal revenue while investing heavily in research and development. The company's financial statements show virtually no revenue (only $533,000 in Q4 2024, likely from collaboration agreements), indicating it has not yet commercialized any products. The company's primary funding sources include equity financing from public and private investors, as well as potential milestone payments and licensing fees from its partnership agreements with companies like Voronoi and Mirati Therapeutics. As a clinical-stage company, ORIC's future revenue model will depend on successfully advancing its pipeline candidates through clinical trials and either licensing them to larger pharmaceutical companies or commercializing them independently. Several factors could significantly impact ORIC's margins and financial performance. Clinical trial success rates represent the most critical factor, as failure in late-stage trials could eliminate years of investment. Regulatory approval timelines affect cash burn duration and time to revenue generation. Competition from larger pharmaceutical companies with similar programs could impact licensing values and market positioning. Manufacturing costs for small molecule drugs and the complexity of precision medicine approaches will influence future gross margins. The company's burn rate of approximately $30-35 million per quarter reflects the high costs of conducting multiple clinical trials simultaneously. This cash consumption pattern is typical for clinical-stage biotechnology companies but creates pressure to either achieve clinical milestones that attract additional funding or secure partnership deals that provide upfront payments and development cost sharing.
Competitive moat
ORIC Pharmaceuticals operates in a highly competitive biotechnology landscape with limited sustainable competitive advantages typical of early-stage drug development companies. The company's primary moat lies in its scientific expertise and intellectual property around specific resistance mechanisms in cancer treatment, particularly its understanding of CD73 biology and PRC2 inhibition approaches. The company's partnerships with Voronoi and Mirati provide some competitive positioning through access to proprietary technologies and compounds that may not be available to competitors. However, these advantages are relatively narrow and could be circumvented by larger pharmaceutical companies with greater resources for parallel development programs. ORIC faces significant competitive threats from major pharmaceutical companies like Roche, Pfizer, and Bristol Myers Squibb, which have substantially larger R&D budgets and can pursue similar targets simultaneously. The precision oncology space is particularly crowded, with numerous companies targeting EGFR mutations and immune checkpoint pathways. The company's small size and limited resources represent both a vulnerability and potential advantage. While ORIC can move quickly on promising targets, it lacks the financial staying power to compete in prolonged development races. The company's survival largely depends on achieving positive clinical results that either attract acquisition interest from larger players or secure significant partnership deals that provide both funding and development expertise. The intellectual property landscape in biotechnology provides some protection, but patents can be designed around, and the company's competitive position will ultimately depend on clinical efficacy and safety data rather than patent protection alone.
Risks & safety
ORIC Pharmaceuticals presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong balance sheet metrics but significant business execution risks. • Cash position and burn rate: The company maintains $49.3 million in cash and short-term investments as of Q1 2025, with a quarterly burn rate of approximately $32.5 million, providing roughly 1.5 quarters of runway at current spending levels. • Debt and solvency: Minimal debt with debt-to-equity ratio of 0.0%, strong current ratio of 12.0x, and quick ratio of 12.0x indicating excellent short-term liquidity and no immediate solvency concerns. • Valuation metrics: Trading at negative P/E ratios due to losses, but Graham net-net working capital ratio of 2.54x suggests the stock trades below liquidation value, providing some downside protection. • Financial runway concerns: The primary risk is the need for additional financing within the next 6-12 months, which could result in significant dilution for existing shareholders or force unfavorable partnership terms. • Clinical trial risks: As a clinical-stage company, the margin of safety depends heavily on successful trial outcomes, which are inherently unpredictable and could result in total loss of investment if programs fail.
Recent development
Based on the available financial data, ORIC Pharmaceuticals has been advancing its clinical pipeline while managing cash resources carefully. The company has maintained consistent quarterly burn rates between $25-35 million, indicating disciplined spending on its three main clinical programs. The minimal revenue generation ($533,000 in Q4 2024) suggests the company has been focused primarily on internal development rather than seeking significant partnership revenues. This approach indicates management's confidence in the value of their pipeline and desire to retain maximum value from successful programs. The company's cash management shows a pattern of periodic fundraising, with cash levels fluctuating from highs of around $66 million to current levels of $49 million. This suggests ORIC has been successful in accessing capital markets when needed, though the declining cash position indicates the need for additional financing in the near term. The consistent advancement of multiple clinical programs simultaneously demonstrates the company's commitment to a diversified pipeline approach, reducing dependence on any single program while increasing overall development costs. This strategy reflects typical clinical-stage biotechnology company operations where portfolio diversification helps manage the high failure rates inherent in drug development.
ORIC company profile · for informational purposes only — not investment advice.
Track ORIC with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free